You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Myelodysplastic

Showing 1 - 25 of 2,825
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Samples of Bone Marrow Aspiration From Myelodysplastic Syndrome

Recruiting
  • Myelodysplastic Syndromes
  • Blood test
  • Jerusalem, Israel
    Shaare Zedek Medical Center
Nov 27, 2023

Luspatercept in Korean Myelodysplastic Syndrome or ß-thalassemia

Not yet recruiting
  • Myelodysplastic Syndrome
  • Beta Thalassemia
  • Seoul, Korea, Republic of
    Bristol-Myers Squibb YH
Oct 3, 2023

MDS Trial in Hangzhou (IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine)

Recruiting
  • Myelodysplastic Syndromes
  • IV Decitabine
  • +2 more
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,Zhejiang University School of Medi
Oct 23, 2023

MDS Trial in Houston (Luspatercept)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Houston, Texas
    M D Anderson Cancer Center
Nov 2, 2023

Acute Myeloid Leukemia, MDS Trial (idarubicin, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Sep 18, 2023

MDS Trial run by the National Cancer Institute (NCI) (KPT-8602, Inqovi)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 30, 2023

MDS, Ferroptosis Trial in Pessac (Biological sampling)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Ferroptosis
  • Biological sampling
  • Pessac, France
  • +2 more
Jun 19, 2023

Lower Risk MDS Per IPSS-R Trial (Luspatercept)

Not yet recruiting
  • Lower Risk MDS Per IPSS-R
  • (no location specified)
Jun 21, 2023

MDS Trial in Seoul (cyclophosphamide, fludarabine, and antithymocyte globulin)

Active, not recruiting
  • Myelodysplastic Syndromes
  • cyclophosphamide, fludarabine, and antithymocyte globulin
  • Seoul, Korea, Republic of
    Asan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023

Haplo-HSCT for Elderly Acute Leukemia/ Myelodysplastic Syndrome

Not yet recruiting
  • Acute Leukemia
  • Myelodysplastic Syndromes
    • Beijing, Beijing, China
      Peking University People's Hospital
    Jun 5, 2023

    Myeloid Malignancy, Acute Myeloid Leukemia, MDS Trial in Rochester (Telehealth Serious Illness Care Program, Education Control)

    Not yet recruiting
    • Myeloid Malignancy
    • +4 more
    • Telehealth Serious Illness Care Program
    • Education Control
    • Rochester, New York
      University of Rochester
    May 24, 2023

    Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • High-Risk and Very High-Risk Myelodysplastic Syndromes
    • (no location specified)
    Jul 25, 2023

    MDS, Myelodysplastic Anemia, Myelodysplastic Syndrome With Isolated Del(5Q) Trial (description of MDS pzatient cohort)

    Recruiting
    • Myelodysplastic Syndromes
    • +5 more
    • description of MDS pzatient cohort
    • Brest, France
      Chu Brest
    Oct 27, 2022

    Myeloid Leukemia, MDS Trial (IFN-?)

    Not yet recruiting
    • Myeloid Leukemia
    • Myelodysplastic Syndromes
    • (no location specified)
    Nov 15, 2023

    MDS Trial (Imetelstat)

    Available
    • Myelodysplastic Syndromes
    • (no location specified)
    Jun 30, 2023

    Myelodysplastic/Myeloproliferative Tumor, Steroid Refractory GVHD, Allogeneic Hematopoietic Cell Transplant Trial in Toronto

    Completed
    • Myelodysplastic/Myeloproliferative Neoplasm
    • +2 more
    • Decidual stromal cells (DSC)
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Jan 8, 2023

    MDS, Chronic Myelomonocytic Leukemia Trial in Tianjin (BC3402, Azacitidine)

    Recruiting
    • Myelodysplastic Syndromes
    • Chronic Myelomonocytic Leukemia
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital, Chinese Acade
    Jul 30, 2023

    MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

    Not yet recruiting
    • Myelodysplastic Syndromes
    • +3 more
    • Subcutaneous azacitidine
    • Oral decitabine/cedazuridine
    • Newcastle, New South Wales, Australia
      Calvary Mater Newcastle
    May 29, 2023

    MDS Trial (Decitabine/Cedazuridine, Magrolimab)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • (no location specified)
    Apr 18, 2023

    Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou

    Recruiting
    • Allogeneic Hematopoietic Stem Cell Transplantation
    • +2 more
    • VEN+AZA+Modified BUCY
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Apr 10, 2023

    Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Scottsdale, Cleveland,

    Completed
    • Chronic Myelomonocytic Leukemia
    • +3 more
    • Scottsdale, Arizona
    • +3 more
    Jan 12, 2023

    Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 Trial in Boston (BXCL701)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Syndrome With Excess Blasts-2
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Jan 26, 2023

    Myelodysplastic Syndrome Trial in Nagoya, Fukuoka, Tokyo (SyB L-1101)

    Completed
    Has Results
    • Myelodysplastic Syndrome
    • SyB L-1101
    • Nagoya, Aichi, Japan
    • +2 more
    Nov 14, 2022

    Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome Trial in Columbus (Azacitidine, Quality-of-Life

    Recruiting
    • Secondary Myelodysplastic Syndrome
    • Therapy-Related Myelodysplastic Syndrome
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Dec 1, 2022

    Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston

    Recruiting
    • Chronic Myelomonocytic Leukemia
    • +5 more
    • Canakinumab
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 7, 2022